Literature DB >> 11485097

Effects of hydroxypyridinone iron chelators in combination with antimalarial drugs on the in vitro growth of Plasmodium falciparum.

K Pattanapanyasat1, K Kotipun, K Yongvanitchit, R C Hider, D E Kyle, D G Heppner, D S Walsh.   

Abstract

Using standard in vitro drug susceptibility methods, we assessed the antimalarial activity of 3 orally administered iron chelators (hydroxypyridinones) alone and in combination with conventional antimalarials drugs (quinine, mefloquine, artesunate, tetracycline, atovaquone) against a chloroquine-resistant Plasmodium falciparum isolate. When tested alone, all iron chelators and antimalarial compounds inhibited the growth of the parasites. IC50 values for iron chelators were 60-70 microM, whereas the IC50 values for antimalarial drugs were in nM ranges, with artesunate being the most potent. The derived isobolograms for the interaction of hydroxypyridinones and antimalarial drugs showed addition or mild antagonism, similar to desferroxamine (Sum of Fractional Inhibitory Concentration, sigma FIC < 0.5 or > 4.0). Despite the absence of synergy with conventional drugs, intrinsic antimalarial activity of hydroxypyridinones supports the continued assessment of these iron chelators as treatment adjuncts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11485097

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  2 in total

1.  Additive in vitro antiplasmodial effect of N-alkyl and N-benzyl-1,10-phenanthroline derivatives and cysteine protease inhibitor e64.

Authors:  Mahardika Agus Wijayanti; Eti Nurwening Sholikhah; Ruslin Hadanu; Jumina Jumina; Supargiyono Supargiyono; Mustofa Mustofa
Journal:  Malar Res Treat       Date:  2010-06-22

2.  Effects of point mutations in Plasmodium falciparum dihydrofolate reductase and dihydropterate synthase genes on clinical outcomes and in vitro susceptibility to sulfadoxine and pyrimethamine.

Authors:  David J Bacon; Doug Tang; Carola Salas; Norma Roncal; Carmen Lucas; Lucia Gerena; Lorena Tapia; A Alejandro Llanos-Cuentas; Coralith Garcia; Lelv Solari; Dennis Kyle; Alan J Magill
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.